Eden Innovations Accelerates EdenCrete and EdenShield Expansion with $4 Million Placement

EdenCrete® Gains Traction Across Multiple Regions

Eden Innovations Ltd (ASX:EDE) has seen its EdenCrete® concrete additive gain significant commercial momentum, with new installations of its Pz7 dosage systems accelerating across North America and India. The quarter ended 30 June 2026 marked the first EdenCrete® Pz7 deployments in Texas and Minnesota, expanding the footprint beyond traditional markets. These installations are part of a broader rollout with Amrize and Quikrete ready-mix concrete plants, alongside Holcim's ongoing use in Ecuador and trials in Canada, Mexico, the UK, and France.

In India, Eden’s trials with independent ready-mix companies, high-rise developers, and the Central Road Research Institute (CRRI) in Delhi produced compelling results. The CRRI report highlighted up to 28% improvement in abrasion resistance, 25% reduction in drying shrinkage, and a 19% boost in compressive strength for EdenCrete® Pz7-enhanced mixes. These gains not only promise stronger and more durable concrete but also enable significant reductions in Ordinary Portland Cement usage, lowering costs and carbon emissions. Eden plans to expand trials beyond Delhi, eyeing India’s booming construction market, now second largest globally, with infrastructure spending hitting an estimated US$135 billion for FY2026–27.

Strategic Appointments to Drive EdenShield® Defence Growth

The EdenShield® division, targeting defence, military, and critical infrastructure sectors, made two pivotal hires this quarter. Julie Bown, a seasoned executive with over 30 years in defence and aerospace including leadership roles at Thales and Raytheon Australia, joined as Strategic Advisor – Defence. Her role focuses on aligning Eden’s technologies with government operational needs and advancing commercialisation pathways within Australia.

Meanwhile, Eden appointed Antanas Guoga, former European Parliament member and global technology investor, as Head of EdenShield® (Europe). Guoga is tasked with building Eden’s European presence, engaging with government contracts, EU and NATO procurement, and forging strategic partnerships. His remuneration is heavily performance-based, linked to share price milestones and revenue targets, underscoring Eden’s commitment to results-driven expansion.

OptiBlend® Continues US Market Growth

Eden’s OptiBlend® retrofit dual-fuel technology, which enables diesel engines to operate on a mix of natural gas without modifications, maintained strong momentum in the US. The company issued US$2.90 million worth of quotations during FY26, including US$1.10 million in June alone, with total US sales rising 33% year-on-year to US$811,000. This growth is driven primarily by demand from data centre operators and drilling customers seeking to reduce fuel costs and emissions while extending generator run times.

Balance Sheet Strengthened by $4.05 Million Placement and Debt Settlement

Eden completed a $4.05 million institutional placement at $0.18 per share, led by L1 Capital Global Opportunities Master Fund, providing fresh capital to accelerate commercialisation efforts across its product lines. Shareholders also approved settling all remaining shareholder loans and accrued director fees via share issuance, effectively clearing the company’s debt and simplifying its capital structure.

The company closed the quarter with $5.2 million in cash and no third-party debt, entering FY2027 with a de-risked balance sheet. Eden also holds approximately 146.3 million in-the-money options that could inject an additional $10.2 million if exercised, although this is subject to market conditions.

Looking Ahead to FY2027

With its financial footing secured, Eden’s priorities include scaling EdenCrete® sales in the Americas, expanding Indian trials into new regions, and converting positive trial outcomes into commercial sales. EdenShield® aims to secure pilot projects and build its European pipeline under Guoga’s leadership, while OptiBlend® focuses on converting its strong US quotation pipeline into orders. The company also plans to advance carbon nanotube concrete R&D for AI and cloud data centre infrastructure applications.

Management, led by Managing Director Dr Allan Godsk Larsen, is actively recruiting to bolster business development, signalling a push to translate promising trial data and strategic hires into tangible revenue growth. However, the path from trial success to commercial scale remains to be navigated amid competitive and regulatory landscapes.